AZD-1222/fexofenadineUrticarial vasculitis and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1918卷 / 1期

关键词：

D O I：

10.1007/s40278-022-20550-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：93 / 93

相关论文

共 50 条

[41] AZD-1222Lack of efficacy: case report
[J]. Reactions Weekly, 2022, 1892 (1) : 58 - 58
[42] Anticoagulants/AZD-1222/immune globulinVITT and lack of efficacy: 6 case reports
[J]. Reactions Weekly, 2022, 1925 (1) : 51 - 51
[43] Azd-1222Lack of efficacy : case report
[J]. Reactions Weekly, 2023, 1959 (1) : 130 - 130
[44] Immunosuppressants/AZD-1222/tozinameranPosterior uveitis and lack of efficacy: 3 case reports
[J]. Reactions Weekly, 2022, 1937 (1) : 246 - 246
[45] AZD-1222/Natalizumab/OcrelizumabBrachial and lumbosacral plexitis and lack of efficacy
[J]. Reactions Weekly, 2024, 2004 (1) : 81 - 81
[46] AZD-1222/tozinameranLack of efficacy
[J]. Reactions Weekly, 2024, 2005 (1) : 152 - 152
[47] Azd-1222/nirmatrelvir+ritonavir/tozinameranRebounds of COVID-19 and lack of efficacy: case report
[J]. Reactions Weekly, 2023, 1940 (1) : 102 - 102
[48] Azd-1222/tozinameranImmune thrombocytopenia: case report
[J]. Reactions Weekly, 2023, 1961 (1) : 90 - 90
[49] Anticoagulants/AZD-1222/immunosuppressantsVaccine-induced immune thrombotic thrombocytopenia and lack of efficacy: case report
[J]. Reactions Weekly, 2022, 1912 (1) : 45 - 45
[50] Azd-1222/elasomeran/tozinameranIgA vasculitis: 12 case reports
[J]. Reactions Weekly, 2023, 1970 (1) : 69 - 69

← 1 2 3 4 5 →